Branimir I. Sikic, M. D.

Clinical Trials

• Recruiting A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
• Recruiting Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia
• Not Recruiting Safety Study of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer
• Not Recruiting AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
• Not Recruiting A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma
• Not Recruiting A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer
• Not Recruiting Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC
• Not Recruiting Phase I/II PTK787/ZK 222584 and Gemcitabine in Advanced Pancreatic Cancer
• Not Recruiting A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
• Not Recruiting Study of XL647 Administered Orally Daily to Patients With Solid Tumors
• Not Recruiting Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
• Not Recruiting Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck
• Not Recruiting Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer (Excluding Squamous Cell)
• Not Recruiting A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
• Not Recruiting A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors
• Not Recruiting An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
• Not Recruiting An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
• Not Recruiting Study of FP-1039 in Subjects With Endometrial Cancers
• Not Recruiting A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer
• Not Recruiting A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors
• Not Recruiting Study of GDC-0973/XL518 in Patients With Solid Tumors
• Not Recruiting Phase 1 Trial of Oral Ixabepilone
• Not Recruiting Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer